Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 2Carcinoma, Hepatocellular 2Stomach Neoplasms 1Rhabdomyosarcoma 1Recurrence 1Pancreatic Ductal Adenocarcinoma 1Pancreatic Diseases 1Neuroblastoma 1Neoplasm Metastasis 1Medulloblastoma 1Liver Neoplasms 1Hepatoblastoma 1Hematologic Neoplasms 1Glioma 1Glioblastoma 1Fibrosis 1Endometrial Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma 1Breast Neoplasms 1Basal Cell Nevus Syndrome 1Astrocytoma 1

Interventions

Gemcitabine 4130-nm albumin-bound paclitaxel 3Pancreaticoduodenectomy 2Oxaliplatin 2Irinotecan 2titanium silicide 1tislelizumab 1sonidegib 1paricalcitol 1mitazalimab 1lenvatinib 1ivosidenib 1irinotecan sucrosofate 1glucoraphanin 1devimistat 1Transurethral Resection of Prostate 1Tissue Banks 1Taxes 1Specimen Handling 1Saline Solution 1S 1 (combination) 1Ropivacaine 1Robotic Surgical Procedures 1Radiomics 1Positron Emission Tomography Computed Tomography 1Parturition 1PEGPH20 1Neoadjuvant Therapy 1Magnetic Resonance Spectroscopy 1Losartan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Ductal Adenocarcinoma × sonidegib × Gastrointestinal × Clear all
NCT01911416 2016-06-09

A Biomarker Study to Identify Predictive Signatures of Response to LDE225 (Hedgehog Inhibitor) In Patients With Resectable Pancreatic Cancer

University of Utah

Phase NA Withdrawn
Gastrointestinal

Pancreatic Ductal Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡